TY  - JOUR
T1  - NAtalizumab risks
AU  - Kuehn BM
Y1  - 2010/03/24
N1  - 10.1001/jama.2010.301
JO  - JAMA
SP  - 1139
EP  - 1139
VL  - 303
IS  - 12
N2  - 
Natalizumab is approved by the FDA for the treatment of multiple sclerosis and Crohn disease. PML is a rare and deadly neurological infection caused by the JC virus, a nearly ubiquitous and usually benign virus that typically affects immunosuppressed individuals. The disorder is also associated with use of natalizumab, and the FDA has received 31 reports of such cases. Because of the risks, natalizumab is currently only available for use through a carefully monitored prescribing program.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.301
UR  - http://dx.doi.org/10.1001/jama.2010.301
ER  -